$50m-plus deal gives Daiichi Sankyo option to Amplimmune's T-cell inhibitor
This article was originally published in Scrip
Daiichi Sankyo is aiming to strengthen its pipeline for autoimmune disorders through an option deal with the private US firm Amplimmune for a novel but still preclinical stage immunomodulating molecule, AMP-110.
You may also be interested in...
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.